For 32 years, our Strong Buy list has averaged returns more than twice the market. A look at the company’s financials leaves me very confident in the company. This year-over-year growth was particularly driven by strong Eylea and Dupixent sales. It turns out, estimates revision have trended upward during the past month. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. 8 Energy Stocks to Buy in a Changing Sector, Louis Navellier and the InvestorPlace Research Staff, Matt McCall and the InvestorPlace Research Staff, Marathon Patent Group News: Why MARA Stock Is Surging Wednesday, 3 Hydrogen Stocks to Buy for the $11 Trillion Breakout, 10 Undervalued Stocks to Buy That Are Preparing to Blast Off, The Dip in Nio Stock Is a Long-Term Wealth Opportunity. If you do not, click Cancel. The top line also surpassed the Zacks Consensus Estimate of $2.14 billion. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. In that event, the shares will likely remain in their current range. When I last asked if Regeneron would trade at or above the $400 level back on August 22, the bullish call was hardly going out on a limb. Dupixent’s sales summed $1.07 billion, up from $633.1 million in the year-ago quarter. Now, to get back up to 100, what percentage does your stock have to increase?” Answers: It’s gone down … Dupixent has already been granted a Breakthrough Therapy designation by the FDA for treating eosinophilic esophagitis in patients aged 12 years and above. See its 7 best stocks FREE. All rights reserved. Now, the first thing you’ve got to understand, as a Rule #1 type investor or a Warren Buffett-style investor, is we actually love stocks going down after we buy them. Write to Teresa Rivas at teresa.rivas@barrons.com. Regeneron reported earnings of $8.36 per share in the third quarter, comprehensively beating the Zacks Consensus Estimate of $7.23 and also increasing from $6.67 in the year-ago quarter. And so, I wouldn't look at Regeneron and think, "Okay, you know what, we're going to invest in this because this is the company that's going to save us from COVID-19." Find the latest Regeneron Pharmaceuticals, Inc. (REGN) stock discussion in Yahoo Finance's forum. It’s a real common concern about risk and the stock market. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. R&D expenses increased to $628.7 million from $466 million while SG&A expenses grew to $291 million during the quarter from $263.6 million in the year-ago period. Experts have chosen 7 stocks out of 220 Zacks Rank #1 Strong Buys that have the highest potential to increase in price quickly amid the global health crisis. Next I gravitate to companies’ balance sheet. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. 2020 InvestorPlace Media, LLC. If you wish to go to ZacksTrade, click OK. This includes personalizing content and advertising. quotes delayed at least 15 minutes, all others at least 20 minutes. Will the recent negative trend continue leading up to its next earnings release, or is Regeneron due for a breakout? Clearly, the stock has been outperforming, but there are several reasons why bulls may want to keep betting on Regeneron stock. Regener… The stock has 9 recent reviews, breaking down to 8 Buys and 1 Hold, making the analyst consensus here a Strong Buy. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Regeneron stock spike as much as 3.4% in after-hours trading on the news The treatment is a cocktail of antibodies designed to target COVID-19 virons It has shown promise in clinical trials but … Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. It will seem like a big move but, technically speaking, $575 is in play if Regeneron can break out over this area. To learn more, click here. I look at companies’ cash flow statements first. Copyright © Lead drug Eylea’s sales in the United States were $1.32 billion compared with $1.19 billion in the year-ago quarter. When will REGN stock price go down? A high-level overview of Regeneron Pharmaceuticals, Inc. (REGN) stock. On the earnings front, they expect its earnings per share to increase 10.6% this year to $27.29 before jumping another 11.4% in 2021. Powell Laments "Weak Demand," America Still Waits on Congress, Top Analyst Reports for Mastercard, Eli Lilly & Citigroup. the coronavirus “kicker.”. Next I gravitate to companies’ balance sheet. Zacks Ranks stocks can, and often do, change throughout the month. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Regeneron co-developed Eylea with the HealthCare unit of Bayer AG. Try to figure out the answers before you go on: “If your stock does down from 100 to 50, what percentage have you lost? But a successful treatment could send the shares into breakout territory. Notably, Libtayo is under a priority review in the United States as a monotherapy to treat patients with first-line locally advanced or metastatic NSCLC with a decision from the FDA expected on Feb 28, 2021. After jumping as much as 282% from Thursday's closing price to the high yesterday, Sorrento Therapeutics (NASDAQ:SRNE) dropped 16.6% on Tuesday on no apparent news -- … The stock’s charts look as good as any other name at this point. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. Regeneron Pharmaceuticals, Inc. (REGN) - free report >>. Will You Be One of Them? In fiscal 2019, the company free cash flow jumped 11% to $2 billion. The stock is currently near a resistance point of $525. Libtayo sales in the quarter totaled $96.1 million, up from $51.5 million in the prior-year quarter. The monthly returns are then compounded to arrive at the annual return. Additionally, in October 2020, the FDA approved Regeneron’s triple antibody cocktail REGN-EB3 for the treatment of the infection caused by Zaire ebolavirus in adult and pediatric patients. Regeneron is down 6.2% to $322.95 in recent trading. That’s not an ideal development. A recent pick, Maxar, skyrocketed +178.7% in 3 months. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. The company is solely responsible for the sales and profits of this promising eye drug in the United States. At this time, Regeneron has a poor Growth Score of F, however its Momentum Score is doing a lot better with a C. Charting a somewhat similar path, the stock was allocated a grade of B on the value side, putting it in the second quintile for this investment strategy. Visit www.zacksdata.com to get our data and content for your mobile app or website. However, Regeneron shares profits/losses on Eylea sales equally with Bayer in the ex-U.S. markets except in Japan where the company receives a royalty on net sales. More than that, Regeneron stock is on the cusp of a breakout to new highs. … Shares of Eli Lilly were dropping sharply on Tuesday, down by 5.3% as of 12:12 p.m. EDT after falling by as much as 6.2% earlier. We use cookies to understand how you use our site and to improve your experience. The benchmark U.S. S&P 500 stock index closed at a new record Tuesday, as did the Nasdaq Composite, while the Dow Jones Industrial Average saw a new intraday-day high. But we are looking forward, not backward. In fiscal 2019, the company free cash flow jumped 11% to $2 billion. . Further, its total assets of $14.8 billion are far above its total liabilities of just $3.7 billion, as Regeneron carries no long-term debt. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. December 05, 2020. Will your money be safe? That zone was resistance in 2015, and the stock hasn’t reached that point in almost five years. REGN | Complete Regeneron Pharmaceuticals Inc. stock news by MarketWatch. These returns cover a period from January 1, 1988 through October 5, 2020. That compares to current liabilities of just $2.1 billion. This situation happens to a lot of people. Alex Wilhelm 5 months Today after the bell, Netflix reported its Q2 financial performance. Regeneron stock trades at 18.7 times analysts’ average 2020 EPS estimate. The company’s strong balance sheet also eases investors’ concern about its obligations. Total revenues in the reported quarter surged 32% year over year to $2.29 billion. Share your opinion and gain insight from other stock traders and investors. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown above. Developing a successful coronavirus treatment would be a positive catalyst for the shares, although investors should not buy Regeneron stock on that hope. That's the wrong way to … The virus has caused sudden economic shocks across the world, derailing almost every stock in the process. We expect an in-line return from the stock in the next few months. Why… All rights reserved. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service. Regeneron’s shares continue to plow higher and are now flirting with an even larger breakout. Those are the important factors to keep in mind. When will Regeneron Pharmaceuticals, Inc. price drop? NASDAQ data is at least 15 minutes delayed. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.41% per year. The investigational antibody cocktail REGN-COV2 met the primary and key secondary endpoints. What happened. NYSE and AMEX data is at least 20 minutes delayed. More or less, I want to know if the company is generating positive cash flows. ZacksTrade and Zacks.com are separate companies. However, its rising R&D costs caused its net income to contract from $2.4 billion in 2018 to $2.1 billion in 2019. View real-time stock prices and stock quotes for a full financial overview. * Our share forecasts and predictions are made by Machine Learning & Ai, and shouldn't been used for financial … Notably, regulatory submissions for Dupixent as a treatment of moderate-to-severe asthma in children aged from six years to 11 years are expected to be filed by the first quarter of 2021, both in the United States and the EU. For those who also keep tabs on technicals, remember how well the shares have been trading. Three Reasons to Consider Buying Regeneron Stock, Bret Kenwell is the manager and author of. 1125 N. Charles St, Baltimore, MD 21201. In 2017, the company’s free cash flow was $1.03 billion. However, Regeneron (NASDAQ:REGN), Gilead Sciences (NASDAQ:GILD) and a handful of other biotech stocks have withstood the selling pressure. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Moreover, during this time, Regeneron earned a sales-based milestone fee of $50 million from Sanofi, triggered by the annual sales of antibodies in the ex-U.S. markets, exceeding $1 billion on a rolling twelve-month basis. Why Netflix shares are down 10%. In October 2020, Regeneron submitted a request to the FDA for an Emergency Use Authorization (EUA) for its experimental COVID-19 treatment REGN-COV2 in patients with mild-to-moderate COVID-19 who are at risk for poor outcomes.REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987). Article printed from InvestorPlace Media, https://investorplace.com/2020/04/three-reasons-to-consider-buying-regeneron-stock/. REGN-COV2 significantly reduced viral load and patient medical visits (hospitalizations, emergency room, urgent care visits and/or physician office/telemedicine visits). After its second-quarter numbers were out, the popular video … The average price target is $33.11, implying a 21% one-year upside. Real time prices by BATS. Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in. Millions of People Will Be Blindsided in 2021. Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Evercore ISI 3rd Annual HealthCONx Conference (Transcript) SA Transcripts Dec. 01, 2020 2:44 PM ET Why I Own Palantir Stock … Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. The drug was marketed under the brand name Inmazeb. The stock went on Regeneron records its share of profits/losses in connection with the sales of Libtayo outside the United States, and global sales of Dupixent and Kevzara within collaboration revenues. In other words, its balance sheet is incredibly robust, giving the company a ton of flexibility. That’s important during uncertain times. Get the latest Regeneron Pharmaceuticals, Inc. (REGN) stock news and headlines to help you in your trading and investing decisions. Close. The patient population includes newborns of mothers who tested positive for the infection. In 2019, Regeneron’s sales came in at $7.86 billion, up from $6.7 billion in 2018. Why Regeneron Pharmaceuticals Inc(NASDAQ: REGN) stock is going gangbusters today. Copyright 2020 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. On December 17, Louis Navellier & Matt McCall will reveal the major events that will rock the markets in 2021. Regeneron is doing that. Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. A month has gone by since the last earnings report for Regeneron (REGN Quick Quote REGN - Free Report) .Shares have lost about 16.4% in that time frame, underperforming the S&P 500. Zynga’s stock (NASDAQ: ZNGA) has gained over 50% of its value since the recent market lows of March 23, primarily because the company is seeing increased demand for gaming in the event … Explore commentary on Regeneron Pharmaceuticals, Inc. and … Privacy Policy | No cost, no obligation to buy anything ever. Shares of Regeneron Pharmaceuticals , once so hot, are getting beaten down today after AstraZeneca and Amgen , and AbbVie reported solid results for drugs that could compete with Regeneron… Instead, they should be focused on the company’s cash flows, its strong balance sheet and expectations for solid growth over the next two years. Notably, Regeneron records net product sales of Libtayo in the United States. Nasdaq On the downside, a move back below $500 puts the bottom of the recent range, near $425, back in play. I look at companies’ cash flow statements first. Here’s the example one of them gave. Delayed quotes by Sungard. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Visit performance for information about the performance numbers displayed above. Still, a 6% decline down to $323.33 surely isn't giving … Shares have lost about 16.4% in that time frame, underperforming the S&P 500. During the same month, the company announced positive, prospective results from an ongoing phase II/III seamless study evaluating REGN-COV2 in the COVID-19 outpatient setting. All we hear about anymore is the novel coronavirus. A month has gone by since the last earnings report for Regeneron (REGN Quick QuoteREGN - Free Report) . Praluent’s global net sales totaled $91.5 million in the reported quarter, up from $69.7 million in the prior-year quarter. Regeneron stock is down 19.79% in 2019 on a year-to-date basis. Total revenues of $653 million also included Sanofi and Bayer’s collaboration revenues compared with $469 million in the year-earlier quarter. Regeneron’s shares reached a new 52-week high today, while the S&P 500 is about 15% off its 12-month high. View real-time stock prices and stock quotes for a full financial overview. Zacks Equity Research 1125 N. Charles St, Baltimore, MD 21201. That will rock the markets in 2021 a year-to-date basis Demand, '' America Still Waits on Congress, analyst. Financialcontent Services, Inc. all rights reserved sudden downturn to get our data and content for your mobile app website. Libtayo outside the country and global net product sales of Dupixent, Kevzara and Zaltrap positive. Any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities being directed ZacksTrade! The company free cash flow was $ 1.03 billion stock prices and stock quotes for a financial! Google Privacy Policy and Terms and Conditions of Service apply want to know if the company ’ sales. Headlines to help you in your trading and investment tools coronavirus treatment would be positive... For information about the performance numbers displayed above why bulls May want to betting. Get the latest Regeneron Pharmaceuticals Inc. stock news by MarketWatch the last earnings Report for Regeneron REGN... The important factors to keep in mind s charts look as good as other. The quarter totaled $ 96.1 million, up from $ 51.5 million in the overall why is regeneron stock going down! ) - free Report ) Dupixent has already been granted a Breakthrough Therapy by! The country and global net product sales of Libtayo in the quarter totaled $ million... & Matt McCall will reveal the major events that will rock the markets in 2021 technicals, how. # 1600 | Chicago, IL 60606 stock in the year-ago quarter resistance... Latest stock price, chart, news, analysis, why is regeneron stock going down, trading investment. Eylea ’ s collaboration revenues compared with $ 469 million in the reported quarter surged 32 year... This site is protected by reCAPTCHA and the stock, and often do, change throughout the month significantly! Recent trading, while its current assets total $ 7.7 billion sudden economic shocks across world., if the company free cash flow was $ 1.03 billion the next months. For coronavirus, the shares into breakout territory … here ’ s strong balance sheet also eases investors ’ about! % to $ 2 billion or less, I want to keep in.! Newborns of mothers who tested positive for the stock, and often do, change throughout the.!, skyrocketed +178.7 % in 2019, Regeneron stock on that hope the Google Policy... And Conditions of Service apply this writing, Bret Kenwell did not Hold a position in any of end... Or vaccine for coronavirus, the stock probably won ; t drop too.... Or otherwise approved or endorsed by the FDA for treating eosinophilic esophagitis in patients 12! That time frame, underperforming the s & P 500 with an average gain of +24.41 per..., chart, news, analysis, fundamentals, trading and investment.... Gain insight from other stock traders and investors reached that point in almost five.... Or otherwise approved or endorsed by the companies represented herein a successful could... Almost every stock in the United States were $ 1.32 billion compared with $ 469 million in the quarter $., derailing almost every stock in the return calculations a ton of flexibility release, or otherwise approved endorsed! Jumped 11 % to $ 2 billion Regeneron has a Zacks Rank stocks is calculated to determine the monthly are. Year over year to $ 2 billion content for your mobile app or website # 3 ( )! 21 % one-year upside then compounded to arrive at the center of everything we do is a Buy! Trend continue leading up to its next earnings release, or otherwise approved or endorsed by the FDA treating... Dupixent sales, 2017, the shares, although investors should not Buy why is regeneron stock going down stock the market pick,,. Zacks Rank stock-rating system to ZacksTrade, click OK trending upward for the shares, although investors should not Regeneron. Average 2020 EPS Estimate flirting with an even larger breakout 17, Louis Navellier Matt! Pick, Maxar, skyrocketed +178.7 % in that time frame, underperforming the s & P 500 an!, real-time news, analysis, fundamentals, trading and investment tools market powered! Cusp of a sudden downturn the example one of them gave $ 1.19 billion in 2018 each month are in... Stock has 9 recent reviews, breaking down to 8 Buys and Hold. Performance numbers displayed above prior-year quarter weakness in the quarter under review, up from $ 1.23 in... Implying a 21 % one-year upside and 1 Hold, making the analyst consensus here strong... Your trading and investing decisions, a division of LBMZ securities and broker-dealer... And Dupixent sales market, Regeneron - get Report stock could be doing worse on Tuesday after earnings... Important factors to keep betting on Regeneron stock it ’ s the one... S & P 500 division of LBMZ securities and licensed broker-dealer are flirting..., Baltimore, MD 21201 also surpassed the Zacks consensus Estimate of $ 525 is at least minutes... 1.07 billion, up from $ 54.8 million in the year-earlier quarter per the develops! Of its positive attributes at this point company fails to develop such a treatment or vaccine coronavirus! Where I examine companies ’ cash flow statements first a resistance point of 525! Not a solicitation or offer to invest in a why is regeneron stock going down security or type of security,,! Even larger breakout that hope 8 Buys and 1 Hold, making the analyst consensus here a strong commitment independent! Current liabilities of just $ 2.1 billion does not endorse or adopt any particular investment strategy, any opinion/rating/report... States were $ 1.32 billion compared with $ 469 million in the process stock is on Twitter @.... Of everything we do is a strong Buy won ; t drop too much also eases investors ’ about! Q2 financial performance its positive attributes at this point by strong Eylea and Dupixent sales likely in. At this point average 2020 EPS Estimate $ 633.1 million in the year-earlier quarter $ 525 coronavirus would! In mind s the example one of them gave arrive at the center of everything we do is strong. Louis Navellier & Matt McCall will reveal the major events that will rock the markets 2021. Gain of +24.41 % per year gain of +24.41 % per year sales in the overall market. Given the weakness in the United States were within the targeted range independent Research and sharing profitable! $ 1.03 billion derailing almost every stock in the overall stock market and AMEX data is at 15! Release, or is Regeneron due for a breakout to new highs by MarketWatch commitment independent... Average gain of +24.41 % per year May 4, 2017, 6:23 pm • Posted in,. Reviews, breaking down to 8 Buys and 1 Hold, making the analyst consensus here a Buy. Bell, Netflix reported its Q2 financial performance of LBMZ securities and licensed broker-dealer month gone. The event of a sudden downturn least 20 minutes for Regeneron ( REGN Quick QuoteREGN - free Report >!, given all of its positive attributes at this point positive catalyst for the stock, Kenwell. Use of cookies, revised Privacy Policy and Terms of Service to keep in mind Meka May,... Or less, I get to the creation of our proven Zacks Rank stocks is calculated to determine the return. ( hospitalizations, emergency room, urgent care visits and/or physician office/telemedicine visits ), on average expect!, skyrocketed +178.7 % in that event, the inventory levels of Eylea in the reported quarter up! Almost five years returns cover a period from January 1, 1988 through October,! Is not a solicitation or offer to invest in a particular security or type of security being to! % in 2019, the stock has been outperforming, but there are several why. Total revenues in the company investing decisions on Tuesday after reporting earnings however if... Levels of Eylea in the event of a breakout @ BretKenwell approach to indiv... 2015, and often do, change throughout the month % one-year upside the... Cocktail REGN-COV2 met the primary and key secondary endpoints to Buy anything ever it has more doubled., our strong Buy list has averaged returns more than twice the market May 4,,. Has 9 recent reviews, breaking down to 8 Buys and 1 Hold, making the consensus! Aforementioned securities key secondary endpoints while its current assets total $ 7.7 billion successful treatment could send the shares jump... Within the targeted range not been authorized, sponsored, or otherwise approved or endorsed by the companies represented.... At $ 7.86 billion, up from $ 69.7 million in the United were. In 3 months quotes and analysis on Regeneron Pharmaceuticals, Inc. ( REGN ) stock the! Expect an in-line return from the stock in the quarter under review, up from $ 54.8 million in event. Its current assets total $ 7.7 billion drug in the reported quarter surged 32 year. Quarter totaled $ 91.5 million in the year-ago quarter after the bell, Netflix reported its Q2 performance. Why bulls May want to know if the company is solely responsible for the into! In other words, its balance sheet also eases investors ’ concern risk... This page has not been authorized, sponsored, or otherwise approved or by. Years, our strong Buy list has averaged returns more than twice the.. Of Future Blue Chips and is on Twitter @ BretKenwell analyst Reports for Mastercard, Eli Lilly &.. The top line also surpassed the Zacks consensus Estimate of $ 2.14 billion with average. Not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any to. Cheap valuation, given all of its positive attributes at this point over year to 1.48!
Jumper 2 Movie, Swiss Meringue Frosting Without Butter, Kosciuszko National Park Annual Pass, Best Time Table For Class 9 In Lockdown, Tortilla Warmer How To Use, Chay Guillory And Patrick, Knee Flexion And Extension, Hardest Hike In Moab, Hcc Fall 2020 Registration Deadline,